The effect of cytokine profiles on the viral response to re-treatment in antiviral-experienced patients with chronic hepatitis C virus infection

Antiviral Research

Volumn 92, Issue 2, 2011, Pages 247-254

  Zhang, Yonghong ^a   Guo, Dandan ^a   Zhao, Yan ^a   Chen, Xiaoyun ^a   Ma, Lina ^a   Jin, Yi ^a   Yan, Huiping ^a   Wu, Hao ^a   Wei, Lai ^b   Dong, Tao ^c   Chen, Xinyue ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Combination therapy; Cytokines; End of treatment virological response (ETVR); Hepatitis C virus (HCV)

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PEGINTERFERON ALPHA; RIBAVIRIN;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LONGITUDINAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RETREATMENT; TREATMENT RESPONSE; VIRUS IMMUNITY; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYTOKINES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TH1 CELLS; TREATMENT OUTCOME; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 80054874110     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.08.009     Document Type: Article

References (24)

1. Ajuebor M.N., Hogaboam C.M., Le T., Proudfoot A.E., Swain M.G. CCL3/MIP-1alpha is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4(+) T cells to the liver. Eur. J. Immunol. 2004, 34:2907-2918.
2. Amati L., Caradonna L., Magrone T., Mastronardi M.L., Cuppone R., Cozzolongo R., Manghisi O.G., Caccavo D., Amoroso A., Jirillo E. Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-alpha/ribavirin. Curr. Pharm. Des. 2002, 8:981-993.
3. Butera D., Marukian S., Iwamaye A.E., Hembrador E., Chambers T.J., Di Bisceglie A.M., Charles E.D., Talal A.H., Jacobson I.M., Rice C.M., Dustin L.B. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005, 106:1175-1182.
4. Chen Y.D., Liu M.Y., Yu W.L., Li J.Q., Peng M., Dai Q., Liu X., Zhou Z.Q. Hepatitis C virus infections and genotypes in China. Hepatobiliary Pancreat. Dis. Int. 2002, 1:194-201.
5. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436:967-972.
6. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
7. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
8. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. American Association for the Study of Liver Diseases.
9. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., Ackrill A.M. Peginterferon alpha-2a (40kD) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann. Intern. Med. 2004, 140:346-355. PEGASYS International Study Group.
10. Helbig K.J., Ruszkiewicz A., Semendric L., Harley H.A., McColl S.R., Beard M.R. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology 2004, 39:1220-1229.
11. Inchauspé G., Honnet G., Bonnefoy J.Y., Nicosia A., Strickland G.T. Hepatitis C vaccine: supply and demand. Lancet Infect. Dis. 2008, 12:739-740.
12. Lauer G.M., Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345:41-52.
13. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
14. Narumi S., Tominaga Y., Tamaru M., Shimai S., Okumura H., Nishioji K., Itoh Y., Okanoue T. Expression of IFN-inducible protein-10 in chronic hepatitis. J. Immunol. 1997, 158:5536-5544.
15. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002. Available at: http://consensus.nih.gov/cons/116/Hepc091202.pdf.
16. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
17. Paul W.E., Zhu J. How are T(H)2-type immune responses initiated and amplified?. Nat. Rev. Immunol. 2010, 10:225-235.
18. Poynard T., Yuen M.F., Ratziu V., Lai C.L. Viral hepatitis C. Lancet 2003, 362:2095-2100.
19. Raghuraman S., Abraham P., Sridharan G., Daniel H.D., Ramakrishna B.S., Shaji R.V. HCV genotype 4 - An emerging threat as a cause of chronic liver disease in Indian (south) patients. J. Clin. Virol. 2004, 31:253-258.
20. Romero A.I., Lagging M., Westin J., Dhillon A.P., Dustin L.B., Pawlotsky J.M., Neumann A.U., Ferrari C., Missale G., Haagmans B.L., Schalm S.W., Zeuzem S., Negro F., Verheij-Hart E., Hellstrand K. Interferon (IFN)-g-inducible protein-10: association with histological results, yiral kinetics, and outcome during treatment with pegylated IFN-a2a and ribavirin for chronic hepatitis C virus infection. J. Infect. Dis. 2006, 194:895-903. DITTO-HCV Study Group.
21. Shields P.L., Morland C.M., Salmon M., Qin S., Hubscher S.G., Adams D.H. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J. Immunol. 1999, 163:6236-6243.
22. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
23. Thomson M., Nascimbeni M., Havert M.B., Major M., Gonzales S., Alter H., Feinstone S.M., Murthy K.K., Rehermann B., Liang T.J. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J. Virol. 2003, 77:862-870.
24. Yoshida E.M., Sherman M., Bain V.G., Cooper C.L., Deschênes M., Marotta P.J., Lee S.S., Krajden M., Witt-Sullivan H., Bailey R.J., Usaty C., Peltekian K. Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can. J. Gastroenterol. 2009, 23:180-184. Pegasys Study Group.